StockNews.AI
WW
StockNews.AI
173 days

WW International, Inc. Announces Fourth Quarter and Full Year 2024 Results

1. WW's total subscribers decreased by 12.2% to 3.3 million in Q4 2024. 2. Revenues fell 10.5% year-over-year, totaling $184.4 million in Q4. 3. Clinical subscription revenues surged 57.9% to $20.5 million in Q4. 4. Operating income improved to $36.2 million, marking a significant turnaround. 5. CEO Tara Comonte has been appointed permanently, aiming for strategic growth.

Earnings
-19.9%Current Return
VS
+1.55%S&P 500
$0.79902/27 04:06 PM EDTEvent Start
$0.6402/28 10:38 PM EDTLatest Updated
68m saved
Insight
Article

FAQ

Why Neutral?

Despite positive operating margins and clinical revenue growth, overall subscription declines hinder bullish sentiment.

How important is it?

The appointment of a permanent CEO and clinical revenue growth spotlight potential recovery, yet subscriber decline tempers opportunity.

Why No Impact?

The strategic focus under the new CEO may yield positive results within the next few quarters.

Related Companies

HLTNKEZNGA
Fourth Quarter 2024 Financial Highlights Total End of Period Subscribers of 3.3 million, including 92 thousand End of Period Clinical SubscribersRevenues of $184.4 million; Subscription Revenues down 7.3% vs. prior year period, including Clinical Subscription Revenues of $20.5 million, up 57.9% vs. prior year periodGross Margin of 69.7%, up 906 basis points vs. prior year period; Adjusted Gross Margin of 69.1%, up 771 basis points vs. prior year periodOperating Income of $36.2 million; Operating Income Margin of 19.6%, up 2,256 basis points vs. prior year period; Adjusted Operating Income of $36.9 million; Adjusted Operating Income Margin of 20.0%, up 967 basis points vs. prior year periodNet Income of $25.1 million; Net Income Margin of 13.6%, up 5,642 basis points vs. prior year period; Adjusted EBITDAS of $50.4 million; Adjusted EBITDAS Margin of 27.4%, up 1,109 basis points vs. prior year period Full Year Fiscal 2024 Financial Highlights Revenues of $785.9 million; Subscription Revenues down 5.6% vs. prior year, including Clinical Subscription Revenues of $78.0 millionGross Margin of 67.8%, up 833 basis points vs. prior year; Adjusted Gross Margin of 68.5%, up 659 basis points vs. prior yearOperating Loss of $236.2 million, including $315.0 million of non-cash impairment charges; Operating Loss Margin of 30.1%; Adjusted Operating Income of $104.8 million; Adjusted Operating Income Margin of 13.3%, up 328 basis points vs. prior yearNet Loss of $345.7 million, including $293.2 million of non-cash impairment charges; Adjusted EBITDAS of $149.3 million; Adjusted EBITDAS margin of 19.0%, up 254 basis points vs. prior year NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or the “Company”) today announced its results for the fourth quarter and full year fiscal 2024 ended December 28, 2024, and announced that the Company’s Board of Directors named Interim President and Chief Executive Officer, Tara Comonte, to a permanent role as President and Chief Executive Officer, effective February 26, 2025. "We are pleased with the momentum in our Clinical business in the Fourth Quarter, reflecting the increasing demand for comprehensive weight management solutions. As more people seek sustainable approaches—including those using or transitioning off medication—our unique combination of science-backed behavioral support, clinical care, and engaged global community allows us to deliver the right solutions at the right time. I am grateful for the Board’s trust in me to lead WeightWatchers through this next phase, and I look forward to building on our progress, working alongside our incredible team, and driving meaningful impact for our members," said Tara Comonte, President and CEO. "At the same time, WeightWatchers is in a period of significant transition as we navigate industry shifts and reposition our business for long-term growth. For more than six decades, we have led innovation in weight management, continuously evolving to meet the changing needs of our members. While we see clear opportunities ahead, executing on them will require careful prioritization as we balance investment in growth with the realities of our capital structure." "I’m excited to join WeightWatchers at this pivotal time," said Felicia DellaFortuna, CFO. "In Q4, we continued to demonstrate disciplined and strategic cost management, which not only drove our year-over-year improvement in Q4’24 Adjusted EBITDAS, but also keeps us on track to achieve our $100 million run-rate cost savings target by the end of 2025. As we look ahead, our focus remains on strengthening our financial foundation to position WeightWatchers for sustained, long-term success." Fourth Quarter 2024 Consolidated Results           % Change % ChangeAdjusted forConstantCurrency(1) Three Months Ended   December 28, 2024 December 30,2023  (in millions except percentages and per share amounts)        Subscription Revenues, net$181.7  $196.1  (7.3%) (7.2%)Other Revenues, net(2)2.7  9.9  (72.8%) (72.8%)Revenues, net$184.4  $206.0  (10.5%) (10.4%)Gross Profit$128.5  $124.9  2.9% 3.0%Non-GAAP Adjustments(1)       Net Restructuring Charges(3)(1.1) 1.5     Adjusted Gross Profit(1)$127.4  $126.4  0.8% 0.9%Operating Income (Loss)$36.2  ($6.0) (100.0%)* (100.0%)*Non-GAAP Adjustments(1)       Franchise Rights Acquired and Goodwill Impairments-  3.6     Net Restructuring Charges(3)0.7  23.6     Adjusted Operating Income(1)$36.9  $21.3  73.5% 73.8%Net Income (Loss)$25.1  ($88.1) (100.0%)* (100.0%)*EPS$0.31  ($1.11) (100.0%)* (100.0%)*Non-GAAP Adjustments(1)         Franchise Rights Acquired Impairments-  0.05       Net Restructuring Charges(3)0.01  0.22       Adjusted EPS(1) $0.32  ($0.84) (100.0%)* (100.0%)*   Total Paid Weeks 45.5  50.4  (9.9%) N/ADigital(4) Paid Weeks37.6  41.0  (8.3%) N/AWorkshops + Digital(5) Paid Weeks6.8  8.7  (22.3%) N/AClinical(6) Paid Weeks1.1  0.7  53.3% N/A           End of Period Subscribers(7)  3.3  3.8  (12.2%) N/ADigital Subscribers2.7  3.1  (11.0%) N/AWorkshops + Digital Subscribers0.5  0.7  (22.7%) N/AClinical Subscribers0.1  0.1  37.8% N/A___________________________________Note: Totals may not sum due to rounding.  *Note: Percentage in excess of 100.0% and not meaningful(1) See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on adjustments to GAAP financial measures.(2) “Other Revenues, net” (formerly known as “Product Sales and Other, net”) consist of revenues from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenues. Prior to fiscal 2024, “Other Revenues, net” included sales of consumer products.(3) See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on the Company’s previously disclosed 2024, 2023, and 2022 restructuring plans, and the reversal of certain of the charges associated therewith.(4) “Digital” refers to providing subscriptions to the Company’s digital product offerings.(5) “Workshops + Digital” refers to providing subscriptions for unlimited access to the Company’s workshops combined with the Company’s digital subscription product offerings.(6) “Clinical” refers to providing subscriptions to the Company’s clinical product offerings provided by WeightWatchers Clinic (formerly referred to as Sequence) combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops.(7) “Subscribers” refers to Digital subscribers, Workshops + Digital subscribers, and Clinical subscribers who participate in recurring bill programs in Company-owned operations.  Q4 2024 Financial Highlights End of Period Subscribers in Q4 2024 were 3.3 million, down 12.2% versus the prior year period, driven by declines in the Digital and Workshops + Digital businesses. End of Period Clinical Subscribers of 92 thousand increased 37.8% versus the prior year period. Total Paid Weeks in Q4 2024 were down 9.9% versus the prior year period, driven by declines in the Digital and Workshops + Digital businesses. The decline in Total Paid Weeks was partially offset by growth in Clinical Paid Weeks, which increased 53.3%. Revenues in Q4 2024 were $184.4 million. On a constant currency basis, Q4 2024 revenues decreased 10.4% versus the prior year period.   Subscription Revenues in Q4 2024 were $181.7 million. On a constant currency basis, these revenues decreased 7.2% versus the prior year period primarily driven by lower recruitments and incoming subscribers in the Company’s non-Clinical businesses. Subscription Revenues benefited from $20.5 million of Clinical Subscription Revenues, which increased 57.9% versus the prior year period. Additionally, Subscription Revenues were negatively impacted by the continued mix shift from the Workshops + Digital business to the Digital business and a higher mix of non-Clinical Subscribers within their initial, lower-priced commitment periods.  Other Revenues in Q4 2024 were $2.7 million. On a constant currency basis, these revenues decreased 72.8% versus the prior year period driven by the closure of the consumer products business at the end of fiscal 2023.   Gross Profit in Q4 2024 was $128.5 million, compared to $124.9 million in the prior year period. Adjusted Gross Profit, which excluded the net reversal of $1.1 million of restructuring charges related to prior years, was $127.4 million. Adjusted Gross Profit in Q4 2023, which excluded the net impact of $1.5 million of restructuring charges, was $126.4 million.  Gross Margin in Q4 2024 was 69.7%, compared to 60.6% in the prior year period. Adjusted Gross Margin in Q4 2024 was 69.1%, up from 61.4% in the prior year period, driven primarily by actions to reduce the fixed cost base within the Workshops + Digital business and the closure of the lower margin consumer products business at the end of fiscal 2023.  Operating Income in Q4 2024 was $36.2 million, compared to an Operating Loss of $6.0 million in the prior year period. Adjusted Operating Income, which excluded the net impact of $0.7 million of restructuring charges, was $36.9 million and benefited from the Company’s previously announced cost savings initiatives. Adjusted Operating Income in Q4 2023, which excluded the net impact of $23.6 million of restructuring charges and non-cash intangible impairment charges of $3.6 million, was $21.3 million. Income Tax Benefit in Q4 2024 was $11.7 million, which reflected the impact of a valuation allowance on the Company’s full year fiscal 2024 financials. In the prior year period, income tax expense was $57.6 million. Net Income in Q4 2024 was $25.1 million compared to a Net Loss of $88.1 million in the prior year period. Adjusted EBITDAS in Q4 2024 was $50.4 million compared to $33.5 million in the prior year period as a result of previously announced cost savings initiatives. Q4 2024 Adjusted EBITDAS margin was 27.4% compared to 16.3% in the prior year period and the highest since the third quarter of 2022.  Diluted Earnings Per Share in Q4 2024 was $0.31 compared to Diluted Net Loss Per Share of $1.11 in the prior year period. Q4 2024 Adjusted Earnings Per Share, which excluded $0.01 net impact of restructuring charges, was $0.32. In the prior year period, Adjusted Net Loss Per Share, which excluded $0.22 of net impact of restructuring charges and $0.05 of non-cash intangible impairment charges, was $0.84. Additionally, certain other items affected year-over-year comparability: In Q4 2024, $0.28 per diluted share positive tax impact arising from the impact of a valuation allowance on the Company’s full year fiscal 2024 financials.In Q4 2023, $0.78 per diluted share negative tax impact due to an increase in the valuation allowance to offset all U.S. deferred tax assets due to the uncertainty of realizing future tax benefits of the assets. Full Year Fiscal 2024 Consolidated Results      % Change % Change Adjusted for Constant Currency(1) Twelve Months Ended   December 28,2024 December 30,2023  (in millions except percentages and per share amounts)         Subscription Revenues, net$777.0  $822.8  (5.6%) (5.6%)Other Revenues, net(2)8.9  66.8  (86.6%) (86.7%)Revenues, net$785.9  $889.6  (11.6%) (11.7%)Gross Profit$533.1  $529.3  0.7% 0.6%Non-GAAP Adjustments(1)       Net Restructuring Charges(3)5.0  21.2     Adjusted Gross Profit(1)$538.1  $550.5  (2.2%) (2.3%)Operating (Loss) Income ($236.2) $22.3  (100.0%)* (100.0%)*Non-GAAP Adjustments(1)        Franchise Rights Acquired and Goodwill Impairments315.0  3.6      Net Restructuring Charges(3)22.2  54.9      Former CEO Separation Expenses3.9  -      Acquisition Transaction Costs-  8.6      Adjusted Operating Income(1)$104.8  $89.5  17.2% 16.7%Net Loss($345.7) ($112.3) 100.0%* 100.0%*EPS($4.34) ($1.46) 100.0%* 100.0%*Non-GAAP Adjustments(1)       Franchise Rights Acquired Impairments3.69  0.05     Net Restructuring Charges(3)0.21  0.54     Former CEO Separation Expenses0.04  -     Acquisition Transaction Costs-  0.10     Adjusted EPS(1) ($0.41) ($0.78) (46.9%) (46.4%)  Total Paid Weeks 196.6  207.2  (5.1%) N/ADigital(4) Paid Weeks162.3  167.9  (3.3%) N/AWorkshops + Digital(5) Paid Weeks30.1  37.7  (20.3%) N/AClinical(6) Paid Weeks4.2  1.6  164.1% N/A        ___________________________________ Note: Totals may not sum due to rounding.  *Note: Percentage in excess of 100.0% and not meaningful(1) See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on adjustments to GAAP financial measures.(2) “Other Revenues, net” (formerly known as “Product Sales and Other, net”) consist of revenues from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenues. Prior to fiscal 2024, “Other Revenues, net” included sales of consumer products.(3) See “Reconciliation of Non-GAAP Financial Measures” attached to this release for further detail on the Company’s previously disclosed 2024, 2023, 2022, 2021, and 2020 restructuring plans, and the reversal of certain of the charges associated therewith.(4) “Digital” refers to providing subscriptions to the Company’s digital product offerings.(5) “Workshops + Digital” refers to providing subscriptions for unlimited access to the Company’s workshops combined with the Company’s digital subscription product offerings.(6) “Clinical” refers to providing subscriptions to the Company’s clinical product offerings provided by WeightWatchers Clinic (formerly referred to as Sequence) combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops.  Full Year Fiscal 2024 Financial Highlights Total Paid Weeks in fiscal 2024 were down 5.1% versus the prior year driven by declines in the Digital and Workshops + Digital businesses. The decline in Total Paid Weeks was partially offset by growth in Clinical Paid Weeks, which increased 164.1%. Revenues in fiscal 2024 were $785.9 million. On a constant currency basis, fiscal 2024 revenues decreased 11.7% versus the prior year. The decline in Revenues was primarily driven by recruitment challenges in the Digital and Workshops + Digital businesses as well as the decline in Other Revenues from the closure of the consumer products business in fiscal 2023. These declines were partially offset by growth in the Clinical business.  Gross Profit in fiscal 2024 was $533.1 million, compared to $529.3 million in the prior year. Adjusted Gross Profit, which excluded the net impact of $5.0 million of restructuring charges, was $538.1 million. Adjusted Gross Profit in fiscal 2023, which excluded the net impact of $21.2 million of restructuring charges, was $550.5 million.  Gross Margin in fiscal 2024 was 67.8%,compared to 59.5% in the prior year. Adjusted Gross Margin in fiscal 2024 was 68.5%, up from 61.9% in the prior year. Adjusted Gross Margin benefited from the cost actions taken to reduce the fixed cost base within the Workshops + Digital business as well as the closure of the lower margin consumer products business at the end of fiscal 2023.  Operating Loss in fiscal 2024 was $236.2 million, compared to Operating Income of $22.3 million in the prior year. Adjusted Operating Income, which excluded $315.0 million of non-cash intangible impairment charges, the net impact of $22.2 million of restructuring charges, and $3.9 million of former CEO separation expenses, was $104.8 million. Adjusted Operating Income in fiscal 2023, which excluded the net impact of $54.9 million of restructuring charges, $8.6 million of acquisition transaction costs, and $3.6 million of non-cash intangible impairment charges, was $89.5 million. Income Tax Expense in fiscal 2024 was $0.5 million, which reflected the impact of a valuation allowance on the Company’s full year fiscal 2024 financials. In the prior year, income tax expense was $38.6 million. Net Loss in fiscal 2024 was $345.7 million compared to Net Loss of $112.3 million in the prior year. Adjusted EBITDAS in fiscal 2024 was $149.3 million compared to Adjusted EBITDAS of $146.4 million in the prior year. Diluted Net Loss Per Share in fiscal 2024 was $4.34 compared to Diluted Net Loss Per Share of $1.46 in the prior year. Fiscal 2024 Adjusted Net Loss Per Share, which excluded $3.69 of non-cash intangible impairment charges, $0.21 of net impact of restructuring charges, and $0.04 of former CEO separation expenses, was $0.41. In the prior year, Adjusted Net Loss Per Share, which excluded $0.54 of net impact of restructuring charges, $0.10 of acquisition transaction costs, and $0.05 of non-cash intangible impairment charges, was $0.78. Additionally, certain other items affected year-over-year comparability: In fiscal 2024, $0.12 per diluted share negative tax impact arising from the impact of a valuation allowance on the Company’s full year fiscal 2024 financials.In fiscal 2023, $0.66 per diluted share negative tax impact due to an increase in the valuation allowance to offset all U.S. deferred tax assets due to the uncertainty of realizing future tax benefits of the assets. Other Items Cash and cash equivalents balance as of December 28, 2024 was $53.0 million. Full Year Fiscal 2025 Guidance The Company is not providing full year fiscal 2025 guidance at this time. Fourth Quarter and Full Year Conference Call and WebcastThe Company has scheduled a conference call today at 5:00 p.m. ET.  During the conference call, Company management will discuss the fourth quarter and full year fiscal 2024 results and answer questions from the investment community. The live webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. Supplemental investor materials will also be available in the same location prior to the start of the webcast. A replay of the webcast will be available on this site for approximately 90 days. Statement regarding Non-GAAP Financial Measures The following provides information regarding non-GAAP financial measures used in this earnings release and today’s scheduled conference call: To supplement the Company's consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. Gross profit, gross margin, operating (loss) income, operating (loss) income margin, net income (loss), net income (loss) margin, diluted (net loss) earnings per share, and selling, general and administrative expenses are discussed both as reported (on a GAAP basis) and as adjusted (on a non-GAAP basis) to exclude, as applicable in a given period: (a) the net impact of the Company’s previously disclosed restructuring plans; (b) the impact of impairment charges for the Company's franchise rights acquired and goodwill; and (c) certain non-recurring costs and adjustments that management believes should be excluded as these do not relate to a recurring part of the core business operations, including acquisition transaction costs and former CEO separation expenses. The Company also presents in the attachments to this release the non-GAAP financial measures: earnings before interest, taxes, depreciation, amortization and stock-based compensation (“EBITDAS”) and EBITDAS margin; EBITDAS as further adjusted for the items described above (“Adjusted EBITDAS”) and Adjusted EBITDAS margin; total debt less unamortized deferred financing costs, unamortized debt discount and cash on hand (i.e., net debt); and a net debt/Adjusted EBITDAS ratio. In addition, the Company presents certain of its financial results on a constant currency basis in addition to GAAP results. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. Management believes these non-GAAP financial measures provide useful supplemental information for its and investors' evaluation of the Company's business performance and are useful for period-over-period comparisons of the performance of the Company's business. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See "Reconciliation of Non-GAAP Financial Measures" attached to this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures. About WW International, Inc. WeightWatchers is a global leader in science-backed weight management, providing an accessible, holistic model of care through our #1 doctor-recommended Points® Program, clinical interventions including weight-loss medications, and community support. Since 1963, we have empowered our millions of members to build healthy habits to live longer lives. Our innovative, trusted spectrum of solutions provides members with the tools and resources they need to reach and sustain their goals wherever they are on their journey. To learn more visit weightwatchers.com or corporate.ww.com. This news release and any attachments include “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives, initiatives, and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim” and similar expressions in this news release and any attachments to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived weight management methods; the Company's failure to continue to retain and grow its subscriber base; the Company’s ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market; the Company's ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to successfully expand into new channels of distribution or respond to consumer trends or sentiment; regulatory, reputational and other risks associated with the Company’s new compounded GLP-1 offering; the ability to successfully implement strategic initiatives; the Company’s ability to evolve its community offerings to meet the evolving tastes and preferences of its members; the effectiveness and efficiency of the Company's advertising and marketing programs, including the strength of the Company's social media presence; the impact on the Company's reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners, including as a result of its acquisition of Weekend Health, Inc., doing business as Sequence (“Sequence”) (the “Acquisition”); the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company's workforce; the Company’s chief executive officer transition; the Company’s ability to successfully make acquisitions or enter into collaborations or joint ventures, including its ability to successfully integrate, operate or realize the anticipated benefits of such businesses, including with respect to Sequence; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company's business; the Company's failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by the Company of leases; the inability to renew certain of the Company's licenses, or the inability to do so on terms that are favorable to the Company; the impact of the Company's substantial amount of debt, debt service obligations and debt covenants, and its exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company's debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the Company's technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company’s ability to successfully integrate and use artificial intelligence in its business; the Company's ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual property rights; the impact of existing and future laws and regulations, including federal and state regulations relating to compounded medications; risks related to the Company's exposure to extensive and complex healthcare laws and regulations as a result of the Acquisition; the outcomes of litigation or regulatory actions; risks and uncertainties associated with the Company's international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; risks related to the Acquisition, including risks that the Acquisition may not achieve its intended results; the possibility that the Company could fail to maintain the listing of its common stock on Nasdaq; risks related to the actions of activist shareholders; and other risks and uncertainties, including those detailed from time to time in the Company's periodic reports filed with the United States Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). For more information, contact:Investors:John Mills or Anna Kate Heller WeightWatchers@icrinc.com Media:Mari SantanaCommunications@ww.com  WW INTERNATIONAL, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS AT (IN THOUSANDS) UNAUDITED               December 28, December 30,    2024   2023 ASSETS    CURRENT ASSETS     Cash and cash equivalents $53,024  $109,366  Receivables (net of allowances: December 28, 2024 - $3,166 and December 30, 2023 - $1,041)  14,428   14,938  Prepaid income taxes  11,676   25,370  Prepaid marketing and advertising  4,969   10,149  Prepaid expenses and other current assets  18,551   19,651  TOTAL CURRENT ASSETS  102,648   179,474 Property and equipment, net  15,798   19,741 Operating lease assets  42,047   52,272 Franchise rights acquired  71,131   386,526 Goodwill  239,583   243,441 Other intangible assets, net  44,631   63,208 Deferred income taxes  16,686   19,683 Other noncurrent assets  17,752   17,685  TOTAL ASSETS $550,276  $982,030 LIABILITIES AND TOTAL DEFICIT    CURRENT LIABILITIES     Portion of operating lease liabilities due within one year $8,168  $9,613  Accounts payable  17,803   18,507  Salaries and wages payable  53,143   79,096  Accrued marketing and advertising  12,805   18,215  Accrued interest  11,322   5,346  Deferred acquisition payable  15,503   16,500  Other accrued liabilities  20,593   22,610  Income taxes payable  2,339   1,609  Deferred revenue  31,655   33,966  TOTAL CURRENT LIABILITIES  173,331   205,462 Long-term debt, net  1,430,643   1,426,464 Long-term operating lease liabilities  44,322   53,461 Deferred income taxes  14,762   41,994 Other noncurrent liabilities  1,590   15,743  TOTAL LIABILITIES  1,664,648   1,743,124 TOTAL DEFICIT     Common stock, $0 par value; 1,000,000 shares authorized; 130,048 shares issued at December 28, 2024 and 130,048 shares issued at December 30, 2023  0   0  Treasury stock, at cost, 49,997 shares at December 28, 2024 and 50,859 shares at December 30, 2023  (3,024,710)  (3,064,628) Retained earnings  1,936,170   2,314,834  Accumulated other comprehensive loss  (25,832)  (11,300) TOTAL DEFICIT  (1,114,372)  (761,094) TOTAL LIABILITIES AND TOTAL DEFICIT $550,276  $982,030        WW INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)UNAUDITED               Three Months Ended   December 28, December 30,    2024   2023 Subscription revenues, net (1) $181,733  $196,087 Other revenues, net (2)  2,680   9,868  Revenues, net  184,413   205,955 Cost of subscription revenues (3)  55,786   67,707 Cost of other revenues  114   13,391  Cost of revenues  55,900   81,098  Gross profit  128,513   124,857 Marketing expenses  48,207   50,920 Selling, general and administrative expenses  44,084   76,312 Franchise rights acquired and goodwill impairments  —   3,633  Operating income (loss)  36,222   (6,008)Interest expense  27,031   24,464 Other (income) expense, net  (4,188)  107  Income (loss) before income taxes  13,379   (30,579)(Benefit from) provision for income taxes  (11,745)  57,556  Net income (loss) $25,124  $(88,135)      Earnings (net loss) per share     Basic $0.31  $(1.11) Diluted $0.31  $(1.11)      Weighted average common shares outstanding     Basic  79,890   79,125  Diluted  81,005   79,125             Note: Totals may not sum due to rounding.    (1) “Subscription revenues, net” consist of the aggregate of: (a) net “Digital Subscription Revenues”, the fees associated with subscriptions for the Company’s Digital offerings; (b) net “Workshops + Digital Subscription Revenues”, the fees associated with subscriptions for the Company’s Workshops + Digital offerings; and (c) net “Clinical Subscription Revenues”, the fees associated with subscriptions for the Company’s Clinical offerings.(2) “Other revenues, net” (formerly known as “product sales and other, net”) consist of revenues from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenues. Prior to fiscal 2024, “Other revenues, net” included sales of consumer products.(3) “Cost of subscription revenues” consists of cost of revenues and operating expenses for the Company's Digital, Workshops + Digital and Clinical services.       WW INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)UNAUDITED               Twelve Months Ended   December 28, December 30,    2024   2023 Subscription revenues, net (1) $776,993  $822,755 Other revenues, net (2)  8,928   66,796  Revenues, net  785,921   889,551 Cost of subscription revenues (3)  250,954   301,062 Cost of other revenues  1,864   59,186  Cost of revenues  252,818   360,248  Gross profit  533,103   529,303 Marketing expenses  236,467   238,387 Selling, general and administrative expenses  217,825   264,950 Franchise rights acquired and goodwill impairments  315,033   3,633  Operating (loss) income  (236,222)  22,333 Interest expense  108,954   95,893 Other (income) expense, net  (1)  72  Loss before income taxes  (345,175)  (73,632)Provision for income taxes  526   38,623  Net loss $(345,701) $(112,255)      Net loss per share     Basic $(4.34) $(1.46) Diluted $(4.34) $(1.46)      Weighted average common shares outstanding     Basic  79,578   76,677  Diluted  79,578   76,677             Note: Totals may not sum due to rounding.    (1) “Subscription revenues, net” consist of the aggregate of: (a) net “Digital Subscription Revenues”, the fees associated with subscriptions for the Company’s Digital offerings; (b) net “Workshops + Digital Subscription Revenues”, the fees associated with subscriptions for the Company’s Workshops + Digital offerings; and (c) net “Clinical Subscription Revenues”, the fees associated with subscriptions for the Company’s Clinical offerings.(2) “Other revenues, net” (formerly known as “product sales and other, net”) consist of revenues from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenues. Prior to fiscal 2024, “Other revenues, net” included sales of consumer products.(3) “Cost of subscription revenues” consists of cost of revenues and operating expenses for the Company's Digital, Workshops + Digital and Clinical services.       WW INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(IN THOUSANDS)UNAUDITED               Twelve Months Ended   December 28, December 30,    2024   2023 Operating activities:     Net loss $(345,701) $(112,255) Adjustments to reconcile net loss to cash (used for) provided by operating activities:     Depreciation and amortization  37,784   52,471  Amortization of deferred financing costs and debt discount  5,018   5,018  Impairment of franchise rights acquired and goodwill  315,033   3,633  Impairment of intangible and long-lived assets  481   1,112  Share-based compensation expense  7,764   15,185  Deferred tax (benefit) provision  (26,578)  19,821  Allowance for doubtful accounts  2,062   1,306  Reserve for inventory obsolescence  72   7,350  Foreign currency exchange rate (gain) loss  (2,276)  263  Changes in cash due to:     Receivables  1,599   17,112  Inventories  91   14,018  Prepaid expenses  18,703   (4,133) Accounts payable  (508)  (54) Accrued liabilities  (14,998)  (11,625) Deferred revenue  (1,780)  1,273  Other long term assets and liabilities, net  (14,624)  (3,598) Income taxes  1,018   (211) Cash (used for) provided by operating activities  (16,840)  6,686 Investing activities:     Capital expenditures  (718)  (2,485) Capitalized software and website development expenditures  (15,692)  (33,816) Cash paid for acquisitions, net of cash acquired  —   (38,362) Other items, net  (5)  (33) Cash used for investing activities  (16,415)  (74,696)Financing activities:     Taxes paid related to net share settlement of equity awards  (839)  (2,241) Proceeds from stock options exercised  —   718  Cash paid for acquisitions  (16,500)  (1,178) Other items, net  (4)  (48) Cash used for financing activities  (17,343)  (2,749)Effect of exchange rate changes on cash and cash equivalents and restricted cash  (2,248)  1,799 Net decrease in cash and cash equivalents and restricted cash  (52,846)  (68,960)Cash and cash equivalents and restricted cash, beginning of period  109,366   178,326 Cash and cash equivalents and restricted cash, end of period $56,520  $109,366        WW INTERNATIONAL, INC. AND SUBSIDIARIESOPERATIONAL STATISTICS (IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED                Three Months Ended    December 28, December 30, Variance  2024 2023        Paid Weeks (1)     Digital Paid Weeks37,595 41,010 (8.3%)Workshops + Digital Paid Weeks6,761 8,703 (22.3%)Clinical Paid Weeks1,103 719 53.3% Total Paid Weeks45,459 50,432 (9.9%)       End of Period Subscribers (2)     End of Period Digital Subscribers2,741 3,079 (11.0%)End of Period Workshops + Digital Subscribers503 652 (22.7%)End of Period Clinical Subscribers92 67 37.8% Total End of Period Subscribers3,336 3,798 (12.2%)              Note: Totals may not sum due to rounding.     (1) The “Paid Weeks” metric reports paid weeks by WW customers in Company-owned operations for a given period as follows: (i) “Digital Paid Weeks” is the total paid subscription weeks for the Company’s Digital offerings; (ii) “Workshops + Digital Paid Weeks” is the total paid subscription weeks for the Company’s Workshops + Digital offerings; (iii) “Clinical Paid Weeks” is the total paid subscription weeks for the Company’s Clinical offerings; and (iv) “Total Paid Weeks” is the sum of Digital Paid Weeks, Workshops + Digital Paid Weeks and Clinical Paid Weeks.(2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end as follows: (i) “End of Period Digital Subscribers” is the total number of Digital subscribers; (ii) “End of Period Workshops + Digital Subscribers” is the total number of Workshops + Digital subscribers; (iii) “End of Period Clinical Subscribers” is the total number of Clinical subscribers; and (iv) “End of Period Subscribers” is the sum of End of Period Digital Subscribers, End of Period Workshops + Digital Subscribers and End of Period Clinical Subscribers.        WW INTERNATIONAL, INC. AND SUBSIDIARIESOPERATIONAL STATISTICS (IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED                Twelve Months Ended    December 28, December 30, Variance  2024 2023        Paid Weeks (1)     Digital Paid Weeks162,290 167,868 (3.3%)Workshops + Digital Paid Weeks30,069 37,742 (20.3%)Clinical Paid Weeks4,247 1,608 164.1% Total Paid Weeks196,606 207,218 (5.1%)       End of Period Subscribers (2)     End of Period Digital Subscribers2,741 3,079 (11.0%)End of Period Workshops + Digital Subscribers503 652 (22.7%)End of Period Clinical Subscribers92 67 37.8% Total End of Period Subscribers3,336 3,798 (12.2%)              Note: Totals may not sum due to rounding.     (1) The “Paid Weeks” metric reports paid weeks by WW customers in Company-owned operations for a given period as follows: (i) “Digital Paid Weeks” is the total paid subscription weeks for the Company’s Digital offerings; (ii) “Workshops + Digital Paid Weeks” is the total paid subscription weeks for the Company’s Workshops + Digital offerings; (iii) “Clinical Paid Weeks” is the total paid subscription weeks for the Company’s Clinical offerings; and (iv) “Total Paid Weeks” is the sum of Digital Paid Weeks, Workshops + Digital Paid Weeks and Clinical Paid Weeks.(2) The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end as follows: (i) “End of Period Digital Subscribers” is the total number of Digital subscribers; (ii) “End of Period Workshops + Digital Subscribers” is the total number of Workshops + Digital subscribers; (iii) “End of Period Clinical Subscribers” is the total number of Clinical subscribers; and (iv) “End of Period Subscribers” is the sum of End of Period Digital Subscribers, End of Period Workshops + Digital Subscribers and End of Period Clinical Subscribers.        WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED                                 Q4 2024 Variance           2024        Constant Q4 2024 Q4 2023 2024  Currency   Currency Constant   vs vs GAAP Adjustment Currency GAAP 2023  2023             Selected Financial Data           Total Revenues$184,413 $189  $184,602 $205,955 (10.5%) (10.4%)Digital Subscription Revenues (1)$113,489 $214  $113,703 $133,459 (15.0%) (14.8%)Workshops + Digital Subscription Revenues (2)$47,772 $(27) $47,745 $49,666 (3.8%) (3.9%)Clinical Subscription Revenues (3)$20,472 $—  $20,472 $12,962 57.9% 57.9%Subscription Revenues (4)$181,733 $187  $181,920 $196,087 (7.3%) (7.2%)Other Revenues (5)$2,680 $2  $2,682 $9,868 (72.8%) (72.8%)                        Note: Totals may not sum due to rounding.            (1) “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings. (2) “Workshops + Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Workshops + Digital offerings. (3) “Clinical Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Clinical offerings.(4) “Subscription Revenues” equal “Digital Subscription Revenues” plus “Workshops + Digital Subscription Revenues” plus “Clinical Subscription Revenues”.(5) “Other Revenues” (formerly known as “product sales and other”) consist of revenues from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenues. Prior to fiscal 2024, “Other Revenues” included sales of consumer products. WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED                                    Full Year 2024 Variance            2024         Constant  Full Year 2024 Full Year 2023 2024  Currency    Currency Constant   vs vs  GAAP Adjustment Currency GAAP 2023  2023              Selected Financial Data           Total Revenues $785,921 $(651) $785,270 $889,551 (11.6%) (11.7%)Digital Subscription Revenues (1)$512,853 $(400) $512,453 $571,074 (10.2%) (10.3%)Workshops + Digital Subscription Revenues (2)$186,139 $(233) $185,906 $221,139 (15.8%) (15.9%)Clinical Subscription Revenues (3)$78,001 $—  $78,001 $30,542 155.4% 155.4%Subscription Revenues (4)$776,993 $(633) $776,360 $822,755 (5.6%) (5.6%)Other Revenues (5)$8,928 $(18) $8,910 $66,796 (86.6%) (86.7%)                          Note: Totals may not sum due to rounding.             (1) “Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Digital offerings. (2) “Workshops + Digital Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Workshops + Digital offerings. (3) “Clinical Subscription Revenues” consist of the fees associated with subscriptions for the Company’s Clinical offerings.(4) “Subscription Revenues” equal “Digital Subscription Revenues” plus “Workshops + Digital Subscription Revenues” plus “Clinical Subscription Revenues”.(5) “Other Revenues” (formerly known as “product sales and other”) consist of revenues from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenues. Prior to fiscal 2024, “Other Revenues” included sales of consumer products. WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES AND PER SHARE AMOUNTS)UNAUDITED                                                                          Q4 2024 Variance                        2024 Constant Currency                      2024    2024   Q4 2024 Q4 2023   Adjusted   Adjusted            Adjusted       2024 vs 2024  vs        Currency Constant Constant       vs 2023  vs 2023   GAAP Adjustment Adjusted Adjustment Currency Currency GAAP Adjustment Adjusted 2023 Adjusted 2023  Adjusted                           Selected Financial Data                         Gross Profit$128,513 $(1,140)(1)$127,373 $114 $128,627 $127,487 $124,857 $1,512(7)$126,369 2.9% 0.8% 3.0% 0.9%Gross Margin 69.7%    69.1%    69.7%  69.1%  60.6%    61.4%                                   Selling, General and Administrative Expenses$44,084 $(1,791)(2)$42,293 $36 $44,120 $42,329 $76,312 $(22,117)(8)$54,195 (42.2%) (22.0%) (42.2%) (21.9%)                           Operating Income (Loss)$36,222 $651(3)$36,873 $69 $36,291 $36,942 $(6,008) $27,262(9)$21,254 (703.0%) 73.5% (704.2%) 73.8%Operating Income (Loss) Margin 19.6%    20.0%    19.7%  20.0%  (2.9%)    10.3%                                   (Benefit from) Provision for Income Taxes$(11,745) $164(4)$(11,581) $21 $(11,724) $(11,560) $57,556 $5,903(10)$63,459 (120.4%) (118.2%) (120.4%) (118.2%)                           Net Income (Loss)$25,124 $487(5)$25,611 $49 $25,173 $25,660 $(88,135) $21,359(11)$(66,776) (128.5%) (138.4%) (128.6%) (138.4%)Net Income (Loss) Margin 13.6%    13.9%    13.6%  13.9%  (42.8%)    (32.4%)                                   Diluted Earnings (Net Loss) Per Share$0.31 $0.01(6)$0.32 $0.00 $0.31 $0.32 $(1.11) $0.27(12)$(0.84) (127.8%) (137.5%) (127.9%) (137.5%)                                                      Note: Totals may not sum due to rounding.                         (1) Excludes the net impact of $47 of charges associated with the Company's previously disclosed 2024 restructuring plan and the reversal of $1,187 of charges associated with the Company's previously disclosed 2023 restructuring plan.(2) Excludes the net impact of $2,184 of charges associated with the Company's previously disclosed 2024 restructuring plan, the reversal of $345 of charges associated with the Company's previously disclosed 2023 restructuring plan and the reversal of $48 of charges associated with the Company's previously disclosed 2022 restructuring plan.(3) Excludes the net impact of (a) $47 of charges and $2,184 of charges associated with the Company's previously disclosed 2024 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (b) the reversal of $1,187 of charges and the reversal of $345 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (c) the reversal of $48 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to selling, general and administrative expenses.(4) Excludes the net impact of $563 of charges associated with the Company's previously disclosed 2024 restructuring plan, the reversal of $387 of charges associated with the Company's previously disclosed 2023 restructuring plan and the reversal of $12 of charges associated with the Company's previously disclosed 2022 restructuring plan.(5) Excludes the net impact of $1,668 of charges associated with the Company's previously disclosed 2024 restructuring plan, the reversal of $1,145 of charges associated with the Company's previously disclosed 2023 restructuring plan and the reversal of $36 of charges associated with the Company's previously disclosed 2022 restructuring plan.(6) Excludes the net impact of $0.02 of charges associated with the Company's previously disclosed 2024 restructuring plan, the reversal of $0.01 of charges associated with the Company's previously disclosed 2023 restructuring plan and the reversal of $0.00 of charges associated with the Company's previously disclosed 2022 restructuring plan.(7) Excludes the net impact of $1,247 of charges associated with the Company's previously disclosed 2023 restructuring plan and $265 of charges associated with the Company's previously disclosed 2022 restructuring plan.(8) Excludes the net impact of $21,893 of charges associated with the Company's previously disclosed 2023 restructuring plan and $224 of charges associated with the Company's previously disclosed 2022 restructuring plan.(9) Excludes (i) the net impact of (a) $1,247 of charges and $21,893 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (b) $265 of charges and $224 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (ii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47.(10) Excludes the net impact of $5,781 of charges associated with the Company's previously disclosed 2023 restructuring plan and $122 of charges associated with the Company's previously disclosed 2022 restructuring plan.(11) Excludes (i) the net impact of $17,359 of charges associated with the Company's previously disclosed 2023 restructuring plan and $367 of charges associated with the Company's previously disclosed 2022 restructuring plan, and (ii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47.(12) Excludes (i) the net impact of $0.22 of charges associated with the Company's previously disclosed 2023 restructuring plan and $0.00 of charges associated with the Company's previously disclosed 2022 restructuring plan, and (ii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $0.03 and $0.02, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $0.00. WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES AND PER SHARE AMOUNTS)UNAUDITED                                                                          Full Year 2024 Variance                         2024 Constant Currency                      2024    2024   Full Year 2024 Full Year 2023   Adjusted   Adjusted            Adjusted       2024  vs 2024  vs        Currency Constant Constant       vs 2023  vs 2023   GAAP Adjustment Adjusted Adjustment Currency Currency GAAP Adjustment Adjusted 2023  Adjusted 2023  Adjusted                           Selected Financial Data                         Gross Profit$533,103 $5,033(1)$538,136 $(554) $532,549 $537,582 $529,303 $21,187(10)$550,490 0.7% (2.2%) 0.6% (2.3%)Gross Margin 67.8%    68.5%    67.8%  68.5%  59.5%    61.9%                                   Selling, General and Administrative Expenses$217,825 $(20,998)(2)$196,827 $(83) $217,742 $196,744 $264,950 $(42,332)(11)$222,618 (17.8%) (11.6%) (17.8%) (11.6%)                           Operating (Loss) Income$(236,222) $341,064(3)$104,842 $(369) $(236,591) $104,404(7)$22,333 $67,152(12)$89,485 (1,157.7%) 17.2% (1,159.4%) 16.7%Operating (Loss) Income Margin (30.1%)    13.3%    (30.1%)  13.3%  2.5%    10.1%                                   Provision for Income Taxes$526 $28,358(4)$28,884 $(91) $435 $28,787(8)$38,623 $14,787(13)$53,410 (98.6%) (45.9%) (98.9%) (46.1%)                           Net Loss$(345,701) $312,706(5)$(32,995) $(278) $(345,979) $(33,336)(9)$(112,255) $52,365(14)$(59,890) 208.0% (44.9%) 208.2% (44.3%)Net Loss Margin (44.0%)    (4.2%)    (44.1%)  (4.2%)  (12.6%)    (6.7%)                                   Diluted Net Loss Per Share$(4.34) $3.93(6)$(0.41) $(0.00) $(4.35) $(0.42) $(1.46) $0.68(15)$(0.78) 196.7% (46.9%) 197.0% (46.4%)                                                      Note: Totals may not sum due to rounding.                (1) Excludes the net impact of $2,497 of charges associated with the Company's previously disclosed 2024 restructuring plan, $2,510 of charges associated with the Company's previously disclosed 2023 restructuring plan and $26 of charges associated with the Company's previously disclosed 2022 restructuring plan.(2) Excludes (i) the net impact of $14,546 of charges associated with the Company's previously disclosed 2024 restructuring plan, $2,612 of charges associated with the Company's previously disclosed 2023 restructuring plan and the reversal of $18 of charges associated with the Company's previously disclosed 2022 restructuring plan, and (ii) the impact of $3,858 of former CEO separation expenses.(3) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of $305,726, $4,074, $2,905 and $2,328 related to its United States, Australia, United Kingdom and New Zealand units of account, respectively, (ii) the net impact of (a) $2,497 of charges and $14,546 of charges associated with the Company's previously disclosed 2024 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (b) $2,510 of charges and $2,612 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (c) $26 of charges and the reversal of $18 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (iii) the impact of $3,858 of former CEO separation expenses recorded to selling, general and administrative expenses.(4) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of $19,839, $1,222 and $726 related to its United States, Australia and United Kingdom units of account, respectively, (ii) the net impact of $4,302 of charges associated with the Company's previously disclosed 2024 restructuring plan, $1,293 of charges associated with the Company's previously disclosed 2023 restructuring plan and $2 of charges associated with the Company's previously disclosed 2022 restructuring plan, and (iii) the impact of $974 of former CEO separation expenses.(5) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of $285,887, $2,852, $2,328 and $2,179 related to its United States, Australia, New Zealand and United Kingdom units of account, respectively, (ii) the net impact of $12,741 of charges associated with the Company's previously disclosed 2024 restructuring plan, $3,829 of charges associated with the Company's previously disclosed 2023 restructuring plan and $6 of charges associated with the Company's previously disclosed 2022 restructuring plan, and (iii) the impact of $2,884 of former CEO separation expenses.(6) Excludes (i) the impact of impairment charges of the Company's franchise rights acquired of $3.59, $0.03, $0.03 and $0.03 related to its United States, Australia, United Kingdom and New Zealand units of account, respectively, (ii) the net impact of $0.16 of charges associated with the Company's previously disclosed 2024 restructuring plan, $0.05 of charges associated with the Company's previously disclosed 2023 restructuring plan and $0.00 of charges associated with the Company's previously disclosed 2022 restructuring plan, and (iii) the impact of $0.04 of former CEO separation expenses.(7) Includes $(69) of currency adjustment associated with the impairment charges of the Company's franchise rights acquired of $4,074, $2,905 and $2,328 related to its Australia, United Kingdom and New Zealand units of account, respectively.(8) Includes $(6) of currency adjustment associated with the impairment charges of the Company's franchise rights acquired of $4,074, $2,905 and $2,328 related to its Australia, United Kingdom and New Zealand units of account, respectively.(9) Includes $(63) of currency adjustment associated with the impairment charges of the Company's franchise rights acquired of $4,074, $2,905 and $2,328 related to its Australia, United Kingdom and New Zealand units of account, respectively.(10) Excludes the net impact of $21,116 of charges associated with the Company's previously disclosed 2023 restructuring plan, the reversal of $4 of charges associated with the Company's previously disclosed 2022 restructuring plan, $96 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $21 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan.(11) Excludes (i) the net impact of $32,627 of charges associated with the Company's previously disclosed 2023 restructuring plan, $1,139 of charges associated with the Company's previously disclosed 2022 restructuring plan and the reversal of $39 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan, and (ii) the impact of $8,605 of acquisition transaction costs.(12) Excludes (i) the net impact of (a) $21,116 of charges and $32,627 of charges associated with the Company's previously disclosed 2023 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (b) the reversal of $4 of charges and $1,139 of charges associated with the Company's previously disclosed 2022 restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, (c) $96 of charges and the reversal of $39 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan recorded to cost of subscription revenues and selling, general and administrative expenses, respectively, and (d) the reversal of $21 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan recorded to cost of subscription revenues, (ii) the impact of $8,605 of acquisition transaction costs recorded to selling, general and administrative expenses, and (iii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47.(13) Excludes (i) the net impact of $13,425 of charges associated with the Company's previously disclosed 2023 restructuring plan, $283 of charges associated with the Company's previously disclosed 2022 restructuring plan, $14 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $5 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan, and (ii) the impact of $1,070 of acquisition transaction costs.(14) Excludes (i) the net impact of $40,318 of charges associated with the Company's previously disclosed 2023 restructuring plan, $852 of charges associated with the Company's previously disclosed 2022 restructuring plan, $43 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $16 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan, (ii) the impact of $7,535 of acquisition transaction costs, and (iii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $2,383 and $1,203, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $47.(15) Excludes (i) the net impact of $0.52 of charges associated with the Company's previously disclosed 2023 restructuring plan, $0.01 of charges associated with the Company's previously disclosed 2022 restructuring plan, $0.00 of charges associated with the Company's previously disclosed 2021 organizational restructuring plan and the reversal of $0.00 of charges associated with the Company's previously disclosed 2020 organizational restructuring plan, (ii) the impact of $0.10 of acquisition transaction costs, and (iii) the impact of impairment charges of the Company's goodwill related to its Republic of Ireland and Northern Ireland reporting units of $0.03 and $0.02, respectively, and the impairment charge of the Company's franchise rights acquired related to its Northern Ireland unit of account of $0.00.                            WW INTERNATIONAL, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (IN THOUSANDS, EXCEPT PERCENTAGES) UNAUDITED                          Three Months Ended Twelve Months Ended    December 28, December 30, December 28, December 30,     2024   2023   2024   2023             Net Income (Loss) $25,124  $(88,135) $(345,701) $(112,255) Interest  27,031   24,464   108,954   95,893  Taxes   (11,745)  57,556   526   38,623  Depreciation and Amortization  8,681   10,007   37,784   45,640  Stock-based Compensation  705   2,346   6,671   11,303   EBITDAS $49,796  $6,238  $(191,766) $79,204   EBITDAS Margin  27.0%   3.0%   (24.4%)  8.9%             Franchise Rights Acquired and Goodwill Impairments  —   3,633 (1) 315,033 (2) 3,633 (1)2024 Plan Restructuring Charges (3)  2,231   —   17,043   —  2023 Plan Restructuring Charges (4)  (1,532)  23,140   5,122   53,743  2022 Plan Restructuring Charges (5)  (48)  489   8   1,135  2021 Plan Restructuring Charges (6)  —   —   —   57  2020 Plan Restructuring Charges (7)  —   —   —   (21) Former CEO Separation Expenses (8)  —   —   3,858   —  Acquisition Transaction Costs (9)  —   —   —   8,605   Adjusted EBITDAS $50,447  $33,500  $149,298  $146,356   Adjusted EBITDAS Margin  27.4%   16.3%   19.0%   16.5%                        Note: Totals may not sum due to rounding.         (1) Impairment charges of the Company's goodwill of $2,383 and $1,203 related to its Republic of Ireland and Northern Ireland reporting units, respectively, and the impairment charge of the Company's franchise rights acquired of $47 related to its Northern Ireland unit of account. (2) Impairment charges of the Company's franchise rights acquired of $305,726, $4,074, $2,905 and $2,328 related to its United States, Australia, United Kingdom and New Zealand units of account, respectively. (3) Charges associated with the Company's previously disclosed 2024 restructuring plan. (4) The reversal of charges or charges, as applicable, associated with the Company's previously disclosed 2023 restructuring plan. (5) The reversal of charges or charges, as applicable, associated with the Company's previously disclosed 2022 restructuring plan. (6) Charges associated with the Company's previously disclosed 2021 organizational restructuring plan. (7) The reversal of charges associated with the Company's previously disclosed 2020 organizational restructuring plan. (8) Certain non-recurring expenses in connection with the separation from the Company of its former Chief Executive Officer. (9) Certain non-recurring transaction costs in connection with the Company's acquisition of Sequence.             WW INTERNATIONAL, INC. AND SUBSIDIARIES RECONCILIATION OF NON-GAAP FINANCIAL MEASURES (IN THOUSANDS, EXCEPT RATIOS) UNAUDITED                                   Trailing Twelve   Q1 2024 Q2 2024 Q3 2024 Q4 2024 Months Net Debt to Adjusted EBITDAS                      Net (Loss) Income$(347,902) $23,269  $(46,192) $25,124  $(345,701) Interest 24,727   28,577   28,619   27,031   108,954  Taxes  55,448   (15,835)  (27,342)  (11,745)  526  Depreciation and Amortization 10,403   9,545   9,155   8,681   37,784  Stock-based Compensation 2,402   2,740   824   705   6,671   EBITDAS$(254,922) $48,296  $(34,936) $49,796  $(191,766)             Franchise Rights Acquired and Goodwill Impairments 257,988 (1) —   57,045 (2) —   315,033  2024 Plan Restructuring Charges (3) —   —   14,812   2,231   17,043  2023 Plan Restructuring Charges (4) 5,493   1,910   (749)  (1,532)  5,122  2022 Plan Restructuring Charges (5) 244   69   (257)  (48)  8  Former CEO Separation Expenses (6) —   —   3,858   —   3,858   Adjusted EBITDAS$8,803  $50,275  $39,773  $50,447  $149,298              Total Debt        $1,430,643  Less: Cash         53,024   Net Debt        $1,377,619               Total Debt to Net Loss         (4.1)X Net Debt to Adjusted EBITDAS         9.2 X                        Note: Totals may not sum due to rounding.          (1) Impairment charges of the Company's franchise rights acquired of $251,431, $4,074, $2,328 and $155 related to its United States, Australia, New Zealand and United Kingdom units of account, respectively. (2) Impairment charges of the Company's franchise rights acquired of $54,295 and $2,750 related to its United States and United Kingdom units of account, respectively. (3) Charges associated with the Company's previously disclosed 2024 restructuring plan. (4) Charges or the reversal of charges, as applicable, associated with the Company's previously disclosed 2023 restructuring plan. (5) Charges or the reversal of charges, as applicable, associated with the Company's previously disclosed 2022 restructuring plan. (6) Certain non-recurring expenses in connection with the separation from the Company of its former Chief Executive Officer.              WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS)UNAUDITED                       Three Months Ended Twelve Months Ended   December 28, December 30, December 28, December 30,   2024 2023 2024 2023          Adjusted Operating Income  $36,873 $21,254  $104,842 $89,485  Other Income (Expense), net  4,188  (107)  1  (72) Depreciation and Amortization  8,681  10,007   37,784  45,640  Stock-based Compensation  705  2,346   6,671  11,303 Adjusted EBITDAS $50,447 $33,500  $149,298 $146,356                     Note: Totals may not sum due to rounding.                  

Related News